Nuformix PLC Oxilio NXP-001 formulation development contract
February 08 2022 - 2:01AM
RNS Non-Regulatory
TIDMNFX
Nuformix PLC
08 February 2022
REACH
8 February 2022
Nuformix plc
("Nuformix" or the "Company")
Oxilio signs a significant service contract with Quotient
Sciences to support the formulation development of NXP-001
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce that following the Company's
signing of an exclusive global licensing agreement with Oxilio Ltd
("Oxilio") for NXP001 on 13 September 2021, Oxilio has progressed
the product and signed a significant service contract with Quotient
Sciences Ltd ("Quotient Sciences") to support the formulation
development of NXP001. NXP001 is a proprietary new form of
aprepitant which is currently marketed for cancer chemotherapy
induced nausea and vomiting ("CINV").
Under the contract Oxilio will work with Quotient Sciences, a
drug development and manufacturing accelerator, to identify and
evaluate the cocrystal formulation of aprepitant to deliver optimal
bioavailability for the treatment of CINV.
Quotient has prior experience of working with the Nuformix
NXP-001 co-crystal and previously developed a capsule and a powder
for oral suspension formulation, evaluating its performance in a
relative bioavailability study versus EMEND (a branded
aprepitant).
Quotient will prepare for Oxilio CMC (chemistry, manufacturing
and controls) batches and stability data to support a clinical
trial application for the new formulation of NXP001.
The Company looks forward to providing further updates on
Oxilio's progress with NXP001 in due course.
Commenting, Alastair Riddell, Executive Chairman of Nuformix,
said: "We are very pleased to see the progress Oxilio is making
with NXP001. Under the exclusive licence we signed with Oxilio we
received an upfront payment, expect to receive milestone payments
when the product completes clinical trials and ultimately royalties
on any sales. This arrangement is allowing Oxilio to progress
NXP001 without cost to the Company whilst we focus on progressing
our two lead assets, NXP002 and NXP004. In relation to NXP002 and
NXP004 we continue to make significant progress and I look forward
to making further announcements in due course."
Enquiries:
Nuformix plc
Dr Alastair Riddell, Executive Chairman Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase I-ready assets with potential for significant value and
early licensing opportunities.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEANAXEFSAEFA
(END) Dow Jones Newswires
February 08, 2022 02:01 ET (07:01 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024